Min­ing re­al world da­ta for drug de­vel­op­ment in­sights, Wood­ford-backed AI firm seeks $77M Lon­don IPO

Putting the words “ar­ti­fi­cial in­tel­li­gence” near drug de­vel­op­ment these days is a sure way to gen­er­ate buzz. But can it sup­port a $77 mil­lion (£60 mil­lion) IPO haul in the UK? For­mer gov­ern­ment min­is­ter and biotech en­tre­pre­neur Paul Drayson is set to find out.

At his firm, which has re­cent­ly been re­named Sen­syne Health, Drayson is com­bin­ing his ex­pe­ri­ence run­ning a vac­cine com­pa­ny and the sci­ence unit for the UK’s De­part­ment for Busi­ness, In­no­va­tion and Skills to build a busi­ness that promis­es to be use­ful for both clin­i­cians and phar­ma­ceu­ti­cal part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER